



PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

Manuscript NO: 63806

Title: Clinical Effects of Antidiabetic Drugs on Psoriasis: The Perspective of Evidence-based Medicine

Reviewer's code: 02476743

Position: Editorial Board

Academic degree: PhD

Professional title: Associate Professor, Director, Statistician

Reviewer's Country/Territory: China

Author's Country/Territory: China

Manuscript submission date: 2021-02-03

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-02-04 00:53

Reviewer performed review: 2021-02-04 01:12

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

From the evidence-based medicine viewpoint, the current evidence demonstrates therapeutic efficacy of pioglitazone, which may be a treatment option in patients with psoriasis and diabetes mellitus. This inspiring result may also indicate that for those patients with both diabetes and psoriasis, pioglitazone may be the optimal choice for treatment. I would like to congratulate the authors for the enthusiasm invested in this editorial.



PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

Manuscript NO: 63806

Title: Clinical Effects of Antidiabetic Drugs on Psoriasis: The Perspective of Evidence-based Medicine

Reviewer's code: 05564292

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Italy

Author's Country/Territory: China

Manuscript submission date: 2021-02-03

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-02-04 14:28

Reviewer performed review: 2021-02-04 18:09

Review time: 3 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

It was my pleasure to review this (invited) editorial describing the role of several antidiabetic drug classes in psoriasis, a common comorbidity of type 2 diabetes. The article is nicely written and shows the authors' concise effort to inform their readers about the potential antipsoriatic effects of TZDs, metformin and GLP1 receptor agonists, and the need for adequately powered and long-term studies. Although the editorial is presented in detail and with most of the relevant information, I would consider minor changes in a revised version: -The mechanisms of GLP1 receptor agonists that determine their antihyperglycemic and anti-inflammatory effects should be briefly mentioned and refereced (i.e. Int J Environ Res Public Health. 2020 May 22;17(10):3664. doi: 10.3390/ijerph17103664.) -"The microenvironment such as inflammation and insulin resistance, as well as genes and epigenetic changes may commonly contribute to the two diseases", this sentence should be properly rephrased. An altered adipose tissue microenvironment in obesity is responsible for insulin resistance and low-grade inflammation at either local or systemic level (e.g. skin). That said, diabetes can relate with a wide spectrum of skin conditions, including but not limited to psoriasis, due to hyperglycemia-induced microvascular damage, altered immune functions, infections, genetic predisposition, etc. In my opinion, this section would benefit of short but deeper insights into the etiological and pathophysiological mechanisms that specifically link diabetes to psoriasis (in all its variants).



RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Diabetes

Manuscript NO: 63806

Title: Clinical Effects of Antidiabetic Drugs on Psoriasis: The Perspective of Evidence-based Medicine

Reviewer's code: 05564292

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Italy

Author's Country/Territory: China

Manuscript submission date: 2021-02-03

Reviewer chosen by: Man Liu

Reviewer accepted review: 2021-04-12 16:15

Reviewer performed review: 2021-04-12 16:21

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Manuscript has been improved according to the reviewer's comments.